Technoclone GmbH of Wien at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

Technoclone GmbH

Brunner Str. 67, 1230 Wien
Austria
Telephone +43 1 86373-0
Fax +43 1 86373-44
sales@technoclone.com

This company is co-exhibitor of
ADVANTAGE AUSTRIA Wirtschaftskammer Österreich

Hall map

MEDICA 2019 hall map (Hall 3): stand F56

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.07  Other diagnostics

Our products

Product category: Other diagnostics

Technoplastin® HIS, Technoclot® PT and PT Owren:

Thromboplastin reagents for determining prothrombin time
according to Owren or Quick method

 for screening of congenital or acquired deficiencies
in the extrinsic and common pathway
 for monitoring of vitamin K antagonists therapy
 aid in the diagnosis of DIC
 for determination of Factors II, V, VII and X
 standardized according the WHO guidelines

More Less

Product category: Other diagnostics

TECHNOCLOT® PT Owren manual

Standardised rabbit brain thromboplastin with the addition
of Fibrinogen and Factor V.
The next generation of Thrombotest® & Normotest®

 TECHNOCLOT® PT Owren is a cost-effective and
high-quality solution for your laboratory
 High sensitivity to factor II, VII and X
 Insensitivity to alterations in factor V and fibrinogen levels
 Good correlation with CoaguCheck®
and other PT systems
on the market
 Calibrated against the WHO Standard RBT/05
(Rabbit brain thromboplastin)
 Very good correlations with inter- and intra assays
 Heparin insensitive up to 1 IU/mL UFH and 1.5 IU/mL LMWH
Advantages and innovations:
 Calibration and control kit specifically for capillary blood method available
 Same sample handling as with Normotest® and Thrombotest®
 Reagent reconstitution with distilled water
 No new equipment requirements
 Applications sheets are available

More Less

About us

Company details

30 YEARS COAGULATION ON OUR MIND
"On the forefront of diagnostic challenges of tomorrow"

Technoclone Herstellung von Diagnostika und Arzneimitteln  GmbH was founded in 1987 by Prof. Dr. Bernd R. Binder (1945 - 2010). The main focus of the company was on monoclonal antibodies against components of the coagulation and the fibrinolytic systems. Technoclone was worldwide the first company offering a complete set of ELISAs and of a novel patented system allowing determination of activity and antigen in the same sample (Actibind) in the field of fibrinolysis.

Acquisition of the former Immuno diagnostics portfolio from the Baxter AG

From 1998 on Technoclone expanded rapidly through the acquisition of the former Immuno diagnostics from Baxter AG and the establishment of an distribution system all over the world.

Production and OEM Products

Technoclone is a world-leading producer of diagnostics tests, equipments and research products in the area of blood clotting. It offers both global as well as speciality coagulation tests. With the fully automated coagulation analyzer the Ceveron® alpha and the semi-automated analyzers the Ceveron® one, four and ten the portfolio was completed. The Ceveron® alpha TGA offers the unique feature of a fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin. Furthermore Technoclone provides a complete range for ADAMTS-13 testing, as well a complete portfolio for the new anticoagulants (DOAC´s) such as for Xa inhibitors and direct thrombin inhibitors.

Technoclone´s high quality in vitro diagnostics and test systems are sold worldwide not only under the Technoclone label but are also found as OEM products in the catalogues of international diagnostics companies.

Research & Development

The focus of Technoclone´s research and development is in the field of thrombosis and cardiovascular diseases, the world leading cause of mortality and morbidity. Research and development is pursued in Technoclone´s own research division and in close cooperation with Universities and international and national research consortia. Technoclone holds at present more than 10 international patents in the field of diagnosis and therapy of vascular diseases.

More Less